NCT07050095 Anxiolytic Effect of Virtual Reality Immersion Versus Midazolam Premedication in Patients Undergoing Dacryocystorhinostomy Surgery
| NCT ID | NCT07050095 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Cairo University |
| Condition | Anxiolytic Effect |
| Study Type | INTERVENTIONAL |
| Enrollment | 40 participants |
| Start Date | 2025-06-01 |
| Primary Completion | 2025-12-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 40 participants in total. It began in 2025-06-01 with a primary completion date of 2025-12-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The aim is to investigate the anxiolytic effect, and hemodynamic stability of using virtual reality immersion in adult patients undergoing Dacryocystorhinostomy (DCR) operation under general anesthesia and to compare its effect to that of using Midazolam as a premedication.
Eligibility Criteria
Inclusion Criteria: * Aged 18-65. * Both sexes. * American Society of Anesthesiologists (ASA) classification: I - II. * Patient undergoing Dacryocystorhinostomy Surgery (DCR) operation under general anesthesia. Exclusion Criteria: * Patient refusal. * Patients with cardiac diseases. * Patients with renal diseases. * Patients with drug sensitivity and seizures. * Substance abuse and addiction. * Claustrophobia. * Patients with cerebrovascular disease. * Psychiatric and cognitive disorder. * Patients with severe teary eyes and blurring of vision. * Patients who express discomfort during the test.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07050095 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 65 Years, studying Anxiolytic Effect. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07050095 currently recruiting?
Yes, NCT07050095 is actively recruiting participants. Contact the research team at drhebasalah593@gmail.com for enrollment information.
Where is the NCT07050095 trial being conducted?
This trial is being conducted at Cairo, Egypt.
Who is sponsoring the NCT07050095 clinical trial?
NCT07050095 is sponsored by Cairo University. The trial plans to enroll 40 participants.